Sarah Scantamburlo, PA
Physician Assistant · Novi, MINPI 1225348568
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 85.0% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $18,889, more than ten times the $1,009 reported in 2021. Among physician assistant clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $162.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$27K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$834
- Sunovion Pharmaceuticals Inc.$825
- Neurocrine Biosciences, Inc.$584
- Alkermes, Inc.$415
- plus $989 from 6 others
What the payments were for
- Consulting fees$10,96035%
- Speaking & faculty fees$11,23236%
- Travel & lodging$2,5138%
- Food & beverage$6,01219%
- Education$4892%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 58 | $26,518 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $1,042 |
| Teva Pharmaceuticals USA, Inc. | 10 | $834 |
| Sunovion Pharmaceuticals Inc. | 58 | $825 |
| Neurocrine Biosciences, Inc. | 10 | $584 |
| Alkermes, Inc. | 9 | $415 |
| Otsuka America Pharmaceutical, Inc. | 8 | $334 |
| Axsome Therapeutics, Inc. | 4 | $201 |
| Johnson & Johnson | 2 | $172 |
| AbbVie | 9 | $162 |
| Lundbeck LLC | 5 | $101 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$13,518
- CAPLYTA$695
- ARISTADA$500
- LYBALVI$400
- INGREZZA$368
- ABILIFY MAINTENA$243
- SPRAVATO$150
- AUSTEDO$135
- ARISTADA INITIO$125
- ABILIFY ASIMTUFII$122
- Auvelity$121
- UZEDY$121
- Austedo XR$114
How this compares
$31,206 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 142 | $453,528 |
| IngrezzaValbenazine Tosylate | 14 | $118,699 |
| RexultiBrexpiprazole | 49 | $85,528 |
| AustedoDeutetrabenazine | 16 | $84,999 |
| Invega TrinzaPaliperidone Palmitate | 11 | $76,102 |
| Abilify MaintenaAripiprazole | 21 | $61,899 |
| LybalviOlanzapine/Samidorphan Malate | 26 | $49,828 |
| CaplytaLumateperone Tosylate | 31 | $44,835 |
| TrintellixVortioxetine Hydrobromide | 64 | $32,884 |
| VraylarCariprazine Hcl | 22 | $28,911 |
| Paliperidone ErPaliperidone | 88 | $24,417 |
| Fluphenazine Hcl | 68 | $16,520 |
| Lurasidone Hcl | 66 | $15,977 |
| Clozapine | 157 | $12,735 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal | $172 | $536,943174 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $334 | $147,42770 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $584 | $118,69914 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $834 | $84,99916 claims |
| Alkermes, Inc.Lybalvi | $415 | $49,82826 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,042 | $44,83531 claims |
| AbbVieVraylar | $162 | $28,91122 claims |
| Axsome Therapeutics, Inc.Auvelity | $201 | $11,83211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Novi
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
- Melissa MickelsonKalamazoo$168K
- Patrick CooneyNew Baltimore$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.